Beam Therapeutics (BEAM) Total Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Total Liabilities for 8 consecutive years, with $316.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 7.98% year-over-year to $316.4 million; the TTM figure through Mar 2026 stood at $316.4 million (down 7.98% YoY), while the FY2025 annual figure was $242.8 million, down 34.42% from the prior year.
• Total Liabilities grew to $316.4 million in Q1 2026 per BEAM's latest filing, from $242.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $635.8 million in Q3 2022 and bottomed at $242.8 million in Q4 2025.
• Historically, Total Liabilities has averaged $458.0 million across 5 years, with a median of $446.3 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 130.54% — and 2025, when it tumbled 34.42%.
• Beam Therapeutics' Total Liabilities stood at $608.2 million in 2022, then declined by 21.35% to $478.4 million in 2023, then fell by 22.6% to $370.3 million in 2024, then sank by 34.42% to $242.8 million in 2025, then jumped by 30.29% to $316.4 million in 2026.
• Business Quant data shows BEAM's Total Liabilities at $316.4 million in Q1 2026, $242.8 million in Q4 2025, and $345.1 million in Q3 2025.